Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

Hyperlipidemia, Familial Combined Clinical Trial

Official title:
Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Hyperlipidemia, Familial Combined
Hyperlipidemias

Clinical Trial Details

NCT number	NCT02035215
Study type	Interventional
Source	Kuhnil Pharmaceutical Co., Ltd.
Contact	Kuhnil Clinical Research Team
Phone	+82-2-2175-9760
Email	jmhong@kuhnil.com
Status	Recruiting
Phase	Phase 3
Start date	January 2014
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00365235` - Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals	N/A
Withdrawn	`NCT00064688` - Genomic Dissection of a QTL Affecting the Lipid Profile	N/A
Completed	`NCT00005368` - Genetic Epidemiology of Hypertriglyceridemia	N/A
Completed	`NCT00754039` - Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol	Phase 4
Completed	`NCT00005313` - Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia	N/A